Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advances study identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://talibc763guf2.atualblog.com/profile